2BBBullish & Bearish
Lisata Therapeutics, Inc. (LSTA) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 23 out of 100.
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022. In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022.
Lisata Therapeutics, Inc.’s current 2BB score is 23 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 0 | Very Low |
| Momentum | 50 | Stable |
| Financial strength | 24 | Weak |
| Quality | 40 | Normal |
| Risk | 52 | Moderate |
| Headquarters | Basking Ridge, New Jersey, United States |
| Founded | 1980 |
| Employees | 21 |
| 52-week range | $0.99 – $5.06 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2026-11-04 | — | — | — | — |
| 2026-08-05 | — | — | — | — |
| 2026-05-06 | — | — | — | — |
| 2026-02-26 | — | -0.5202 | — | — |